Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 20,994 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Completed Phase 3 Interventional

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

NCT00002191
View directory record Official record
Conditions
Protozoan Infections, HIV Infections
Interventions
Albendazole
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:39 AM EDT
Active, not recruiting No phase listed Observational

Database Retrieval for the Comprehensive Shoulder

NCT03409718
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision, Correction of Functional Deformity, Fracture of Proximal End of Humerus, Cuff Tear Arthropathy
Interventions
Biomet Comprehensive Shoulder System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

NCT00537290
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Rituximab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 21, 2026, 9:39 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Altered Immune Response to Exercise in Patients With Fibromyalgia Before and After a Mind-body Intervention

NCT03441997
View directory record Official record
Conditions
Fibromyalgia
Interventions
Mind-body exercise, Light mobility exercises
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT02506959
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

NCT04001803
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA+RPV LA
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

NCT00000143
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir implant and oral ganciclovir, Cidofovir intravenous
Device · Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
19
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00075725
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
3,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
208
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 21, 2026, 9:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668
View directory record Official record
Conditions
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions
Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care

NCT05925374
View directory record Official record
Conditions
Social Stigma, Substance Use Disorders, HIV Infections, Physician-Patient Relations
Interventions
Substance use stigma training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

NCT00096018
View directory record Official record
Conditions
Leukemia
Interventions
fludarabine phosphate, thalidomide
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 21, 2026, 9:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ketosis Prone Diabetes in African-Americans

NCT00426413
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
Interventions
pioglitazone
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 4 Interventional

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

NCT00102882
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, salmeterol xinafoate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fresno, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823
View directory record Official record
Conditions
HIV Infection
Interventions
3MV, PCC, Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Behavioral · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 22 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

NCT00569179
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic
Interventions
CliniMACS CD34 Reagent System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 21, 2026, 9:39 AM EDT
Enrolling by invitation Not applicable Interventional

Pilot RCT: FQHC Intervention for Uptake of CGM in Low-Income Adults With T1D

NCT06487962
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CGM Intervention, SMBG Control Condition
Device · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Middletown, Connecticut • Vero Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 21, 2026, 9:39 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

NCT01878708
View directory record Official record
Conditions
T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
Interventions
PEG-L-asparaginase, Dexamethasone acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06059391
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.

NCT00002097
View directory record Official record
Conditions
HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Argus Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 9:39 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Bortezomib, Iberdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
43
States / cities
Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

NCT00910910
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Lenalidomide, Chlorambucil
Drug
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
28
States / cities
Escondido, California • Whittier, California • New Britain, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 21, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional Results available

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

NCT05415410
View directory record Official record
Conditions
GVHD
Interventions
Apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Stanford, California • Iowa City, Iowa • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 9:39 AM EDT
Completed No phase listed Observational

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers

NCT00253682
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, HIV Infections, Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Up to 2 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 21, 2026, 9:39 AM EDT